Allergy News and Research

RSS

The term allergy encompasses a wide range of conditions; it is not a disease in itself. In 1906 Clemens von Pirquet was the first to describe allergies as a changed or altered reaction of the immune system in response to exposure to foreign proteins. These days the term allergy – medically termed hypersensitivity, signifies an exaggerated reaction to foreign substances.

Study reports low incidence of severe COVID-19 among vaccinated and boosted individuals

A large study of COVID-19 disease following vaccination and booster, published in the Journal of the American Medical Association (JAMA), reports surprisingly low incidence, especially in individuals younger than 65 years of age with no high-risk conditions.

6 Oct 2022

Impaired immune responses not responsible for COVID-19 rebound, findings suggest

Findings from a small study of eight patients published in Clinical Infectious Diseases suggest that COVID-19 rebound is likely not caused by impaired immune responses.

6 Oct 2022

Targeted cognitive behavioral therapy can reduce food allergy-related anxiety for children and parents

Children with food allergies, along with their parents, often experience heightened anxiety over risks of casual contact with food allergens.

4 Oct 2022

Early-stage clinical trial evaluating bacteriophage therapy in adults with cystic fibrosis begins

Enrollment has begun in an early-stage clinical trial evaluating bacteriophage therapy in adults with cystic fibrosis (CF) who carry Pseudomonas aeruginosa (P. aeruginosa) in their lungs.

4 Oct 2022

Study provides new insights into the underlying physiology of mevalonate kinase deficiency

A new study from the Garvan Institute of Medical Research shows how rises in core body temperature may trigger the inflammatory flares in people with a rare genetic autoinflammatory disease.

3 Oct 2022

Novel peanut-specific human IgE monoclonal antibodies may uncover new therapeutic targets for peanut allergy

A recent Frontiers in Immunology journal study by University of North Carolina at Chapel Hill and Vanderbilt University researchers has created an in vitro system to determine potential therapeutics targeting sensitized effector cells based on human, allergen-specific, Immunoglobulin E (IgE) monoclonal antibodies (mAbs).

2 Oct 2022

Gut microbiome could contribute to a person's risk for HIV infection, research suggests

New UCLA-led research suggests certain gut bacteria -- including one that is essential for a healthy gut microbiome – differ between people who go on to acquire HIV infection compared to those who have not become infected.

30 Sep 2022

COVID-19 booster shots essential for maintaining long-term immunity against infection in older adults

In a study of more than 80 men and women from Baltimore, Maryland, Johns Hopkins researchers have added to evidence that COVID-19 booster shots are essential for maintaining long-term immunity against infection, particularly among older adults.

29 Sep 2022

Novel microfluidic device mimics nutrient exchange between mother and fetus affected by placental malaria

Placental malaria as a consequence of Plasmodium falciparum infections can lead to severe complications for both mother and child.

26 Sep 2022

UTHSC professor receives $5 million to explore the gut as therapeutic target for treating disease

Radhakrishna Rao, PhD, vice-chair and professor in the Department of Physiology at the University of Tennessee Health Science Center (UTHSC), has received two large national awards totaling $5 million for separate studies involving the gut as a therapeutic target for treating disease.

26 Sep 2022

Study paves the way for new therapies, vaccines that lead to stronger immunity against Covid-19

Why do some people become seriously ill with Covid-19, while others have no symptoms at all? The answer may lie in the proteins our immune system has previously been exposed to.

23 Sep 2022

Most people infected with SARS-CoV2 recover within 12 months, study finds

A McMaster University-led study has found that most people infected with the SARS-CoV2 virus recover within 12 months, irrespective of the severity.

22 Sep 2022

New guideline for the evaluation and testing of patients with penicillin allergies

A new guideline published in Clinical & Experimental Allergy will help clinicians evaluate and test patients for potential penicillin allergies.

21 Sep 2022

BU investigator wins highly competitive awards to study the role of proteases in regulation of cellular defenses

Mohsan Saeed, PhD, assistant professor of biochemistry at Boston University School of Medicine (BUSM), has received a five-year, $2 million R35 grant from the National Institute of General Medical Sciences, as well as a five-year, $2.5 million R01 grant from the National Institute of Allergy and Infectious Diseases.

20 Sep 2022

UCLA announces participation in a phase 3 trial evaluating tecovirimat for the treatment of monkeypox

The UCLA Clinical AIDS Research and Education (CARE) Center today announced its participation in STOMP (Study of Tecovirimat for Human Monkeypox Virus), or A5418, a phase 3, randomized, placebo-controlled, double-blind trial evaluating the safety and efficacy of tecovirimat for the treatment of human monkeypox.

16 Sep 2022

UW Medicine researchers seek participants for Phase 3 clinical trial of a drug to treat monkeypox

UW Medicine researchers are recruiting participants for a Phase 3 clinical trial of a drug to treat the monkeypox virus.

16 Sep 2022

Mortality risk higher among children with primary immunodeficiency diseases infected with SARS-CoV-2

Children with certain immunodeficiency diseases carry mutations in genes that regulate the body's immune system against viral infections and they have a higher mortality rate due to COVID-19.

16 Sep 2022

New genomic test can predict a patient's risk of developing severe COVID-19, research suggests

A genomic test being developed by a Charlottesville, Va., company can predict a patient's risk of developing severe COVID-19, new research from UVA Health suggests.

16 Sep 2022

Itchy eczema in children finally gets relief

This is the first large-scale, randomized, placebo-controlled trial of a monoclonal antibody in any skin disease, including eczema, in children as young as six months. The study, which included 31 sites in Europe and North America, was published in The Lancet.

16 Sep 2022

Machine learning can help create proteins much more accurately, quickly than previously possible

Over the past two years, machine learning has revolutionized protein structure prediction. Now, three papers in Science describe a similar revolution in protein design.

15 Sep 2022

Allergy News and Research

Further Reading

Study reports low incidence of severe COVID-19 among vaccinated and boosted individuals

Impaired immune responses not responsible for COVID-19 rebound, findings suggest

Targeted cognitive behavioral therapy can reduce food allergy-related anxiety for children and parents

Early-stage clinical trial evaluating bacteriophage therapy in adults with cystic fibrosis begins

Study provides new insights into the underlying physiology of mevalonate kinase deficiency

Novel peanut-specific human IgE monoclonal antibodies may uncover new therapeutic targets for peanut allergy

Gut microbiome could contribute to a person's risk for HIV infection, research suggests

COVID-19 booster shots essential for maintaining long-term immunity against infection in older adults

Novel microfluidic device mimics nutrient exchange between mother and fetus affected by placental malaria

UTHSC professor receives $5 million to explore the gut as therapeutic target for treating disease

Study paves the way for new therapies, vaccines that lead to stronger immunity against Covid-19

Most people infected with SARS-CoV2 recover within 12 months, study finds

New guideline for the evaluation and testing of patients with penicillin allergies

BU investigator wins highly competitive awards to study the role of proteases in regulation of cellular defenses

UCLA announces participation in a phase 3 trial evaluating tecovirimat for the treatment of monkeypox

UW Medicine researchers seek participants for Phase 3 clinical trial of a drug to treat monkeypox

Mortality risk higher among children with primary immunodeficiency diseases infected with SARS-CoV-2

New genomic test can predict a patient's risk of developing severe COVID-19, research suggests

Itchy eczema in children finally gets relief

Machine learning can help create proteins much more accurately, quickly than previously possible

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News